These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16027730)

  • 1. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
    Starczynowski DT; Reynolds JG; Gilmore TD
    Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
    Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
    Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
    Fan Y; Gélinas C
    Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells.
    Starczynowski DT; Reynolds JG; Gilmore TD
    Oncogene; 2003 Oct; 22(44):6928-36. PubMed ID: 14534540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
    Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
    Epinat JC; Dvorin EL; Gilmore TD
    Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
    Sif S; Capobianco AJ; Gilmore TD
    Oncogene; 1993 Sep; 8(9):2501-9. PubMed ID: 8361761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kappa B binding site.
    Capobianco AJ; Gilmore TD
    Oncogene; 1991 Dec; 6(12):2203-10. PubMed ID: 1766669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
    Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
    Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G; Gilmore TD
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
    Fan Y; Rayet B; Gélinas C
    Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
    Sarkar S; Gilmore TD
    Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells.
    Kalaitzidis D; Ok J; Sulak L; Starczynowski DT; Gilmore TD
    Oncogene; 2004 Sep; 23(45):7580-7. PubMed ID: 15326488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation.
    Zurovec M; Petrenko O; Roll R; Enrietto PJ
    Oncogene; 1998 Jun; 16(24):3133-42. PubMed ID: 9671392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells.
    Sun SC; Maggirwar SB; Harhaj EW; Uhlik M
    Oncogene; 1999 Feb; 18(7):1401-9. PubMed ID: 10050877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
    Morrison LE; Boehmelt G; Enrietto PJ
    Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cRel-TD kinase: a serine/threonine kinase binding in vivo and in vitro c-Rel and phosphorylating its transactivation domain.
    Fognani C; Rondi R; Romano A; Blasi F
    Oncogene; 2000 Apr; 19(18):2224-32. PubMed ID: 10822372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
    Nehyba J; Hrdlicková R; Bose HR
    Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
    Majid SM; Liss AS; You M; Bose HR
    Oncogene; 2006 Feb; 25(5):756-68. PubMed ID: 16186799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.